Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study.
- DOI
- 10.1007/s13555-026-01760-8
- Published
- 2026 Jun
- Container
- Dermatology and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-026-01760-8,
title = {Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study.},
author = {Facheris P and Piscazzi F and Fiorillo G and Valenti M and Costanzo A and Borroni RG},
year = {2026},
journal = {Dermatology and therapy},
doi = {10.1007/s13555-026-01760-8},
url = {https://doi.org/10.1007/s13555-026-01760-8}
}RIS
TY - JOUR TI - Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study. AU - Facheris P AU - Piscazzi F AU - Fiorillo G AU - Valenti M AU - Costanzo A AU - Borroni RG PY - 2026 JO - Dermatology and therapy DO - 10.1007/s13555-026-01760-8 UR - https://doi.org/10.1007/s13555-026-01760-8 ER -
APA
P, F., F, P., G, F., M, V., A, C., & RG, B. (2026). Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study.. Dermatology and therapy. https://doi.org/10.1007/s13555-026-01760-8
Source records
- pubmed · retrieved 2026-09-26T06:55:08.631Z